Tin tức & Cập nhật
Xem bài viết Niệu khoa
Xem

Circulating 11-oxygenated androgens predict survival in localized prostate cancer
In men with localized prostate cancer undergoing radical prostatectomy and treated with 5α-reductase inhibitor (5-ARI), preoperative levels of circulating 11-oxygenated androgens can indicate either disease progression or improved survival, a recent study has found.
Circulating 11-oxygenated androgens predict survival in localized prostate cancer
01 Feb 2023
MRI- vs CT- guided radiotherapy for localized prostate cancer linked to lower toxicity, symptom burden
Magnetic resonance imaging (MRI) guidance in stereotactic body radiotherapy (SBRT) for prostate cancer offers significant advantage over computed tomography (CT) guidance, with lower physician-scored toxic effects and patient-reported symptom burden, according to the results of the phase III MIRAGE* study.
MRI- vs CT- guided radiotherapy for localized prostate cancer linked to lower toxicity, symptom burden
19 Jan 2023
Repeat transurethral resection of bladder tumour predicts but does not improve survival
Repeat transurethral resection of bladder tumour prior to radical cystectomy, regardless of whether or not neoadjuvant chemotherapy is administered, does not seem to improve survival in patients with muscle-invasive bladder cancer, reveals a recent study.
Repeat transurethral resection of bladder tumour predicts but does not improve survival
07 Jan 2023
5α-reductase inhibitor treatment implicated in dementia
Men who are receiving treatment with 5α-reductase inhibitors (5-ARIs) are at increased risk of dementia in the immediate period after initiating treatment, a study has shown. Of note, both finasteride and dutasteride are associated with depression, but neither of them is linked to suicide.
5α-reductase inhibitor treatment implicated in dementia
05 Jan 2023
Relugolix effective, well tolerated in Asian men with advanced prostate cancer
In the subgroup analysis of the HERO trial, the first-in-class oral, highly selective, GnRH* antagonist relugolix was effective and well tolerated in Asian men with advanced prostate cancer.




